Christopher Ryan Sullivan is Chief Financial Officer of Avalo Therapeutics Inc.
Person profile
Latest filings (excl ownership)
No filings
Latest ownership filings
4
Avalo Therapeutics, Inc.
13 Jun 23
4
Avalo Therapeutics, Inc.
17 May 23
4
Avalo Therapeutics, Inc.
15 Feb 23
4
Avalo Therapeutics, Inc.
7 Oct 22
4
Avalo Therapeutics, Inc.
10 Mar 22
4
Avalo Therapeutics, Inc.
14 Dec 21
4
Cerecor Inc.
28 Jan 21
4
Cerecor Inc.
14 Dec 20
4
Cerecor Inc.
11 Jun 20
3
Cerecor Inc.
4 May 20
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Jun 23 | AVTX Avalo Therapeutics | Common Stock | Buy | Acquire P | No | No | 3.42 | 511 | 1.75 k | 1,262 |
15 May 23 | AVTX Avalo Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 2.75 | 40,000 | 110.00 k | 40,000 |
13 Feb 23 | AVTX Avalo Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 2.98 | 40,000 | 119.20 k | 40,000 |